These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 8853918)

  • 1. Quantitative analysis of In-111 satumomab pendetide immunoscintigraphy. An aid to visual interpretation of images in patients with suspected carcinomatosis.
    Neal CE; Johnson DL; Cornwell VL; Markwell S
    Clin Nucl Med; 1996 Aug; 21(8):638-42. PubMed ID: 8853918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of radioimmunoscintigraphy and computed tomography scan prior to reassessment laparotomy of patients with ovarian carcinoma. A preliminary report.
    Method MW; Serafini AN; Averette HE; Rodriguez M; Penalver MA; Sevin BU
    Cancer; 1996 Jun; 77(11):2286-93. PubMed ID: 8635097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indium-111 OncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences. Early observations.
    Bohdiewicz PJ; Scott GC; Juni JE; Fink-Bennett D; Wilner F; Nagle C; Dworkin HJ
    Clin Nucl Med; 1995 Mar; 20(3):230-6. PubMed ID: 7750217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oncoscint for detection of disseminated colorectal and ovarian cancer.
    Med Lett Drugs Ther; 1993 Jun; 35(898):52-3. PubMed ID: 8497207
    [No Abstract]   [Full Text] [Related]  

  • 5. In-111 CYT-103 immunoscintigraphy in the imaging of ovarian carcinoma.
    Neal CE; Baker MR; Hilgers RD; Fanning J; Burke RC; Snodgrass J; Cull RD
    Clin Nucl Med; 1993 Jun; 18(6):472-6. PubMed ID: 8319398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. OncoScint image atlas.
    Maguire RT
    Targeted Diagn Ther; 1992; 6():141-75. PubMed ID: 1576344
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical experience with radiolabelled monoclonal antibodies in the detection of colorectal and ovarian carcinoma recurrence and review of the literature.
    Pinkas L; Robins PD; Forstrom LA; Mahoney DW; Mullan BP
    Nucl Med Commun; 1999 Aug; 20(8):689-96. PubMed ID: 10451876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunoscintigraphy in patients with colorectal, ovarian, and prostate cancer. Results with site-specific immunoconjugates.
    Maguire RT; Pascucci VL; Maroli AN; Gulfo JV
    Cancer; 1993 Dec; 72(11 Suppl):3453-62. PubMed ID: 8242578
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoscintigraphy using 111InCyt103 prior to second look laparotomy in ovarian cancer. A pilot study.
    Hempling RE; Piver MS; Baker TR; Bakshi S; Gilani SS
    Am J Clin Oncol; 1994 Aug; 17(4):331-4. PubMed ID: 8048395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radioimmunodetection of colorectal carcinoma.
    Artiko V; Obradovic V; Davidovic B; Petrovic N; Petrovic M; Krivokapic Z; Kecmanovic D; Pesko P; Djukic V; Milosavljevic T; Adanja G; Vlajkovic M
    Hepatogastroenterology; 2003; 50(52):1029-31. PubMed ID: 12845972
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intense uptake of In-111 satumomab pendetide in an inflammatory mass.
    Silberstein EB; Saeks E
    Clin Nucl Med; 1996 Jan; 21(1):53-5. PubMed ID: 8741891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Indium 111-labeled antibodies in the detection of colorectal carcinoma].
    Artiko V; Obradović V; Davidović B; Petrović N; Petrović M; Krivokapić Z; Pavlov M; Adanja G; Sobić D; Vlajković M; Pavlović S; Rebić R
    Acta Chir Iugosl; 2003; 50(4):43-6. PubMed ID: 15307496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Planar, SPET and three-dimensional immunoscintigraphy of suspected recurrent colorectal cancer using 111In-B72.3 (Oncoscint CR-OV): effect of administered activity.
    Perkins AC; Vincent RM; Wastie ML; Denton GW; Amar S; Hardcastle JD
    Nucl Med Commun; 1994 Dec; 15(12):981-90. PubMed ID: 7715898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoscintigraphy with 111In-satumomab pendetide in patients with colorectal adenocarcinoma: performance and impact on clinical management.
    Corman ML; Galandiuk S; Block GE; Prager ED; Weiner GJ; Kahn D; Abdel-Nabi H; Mitchell EP; Pascucci VL; Maroli AN
    Dis Colon Rectum; 1994 Feb; 37(2):129-37. PubMed ID: 8306832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlative imaging with monoclonal antibodies in colorectal, ovarian, and prostate cancer.
    Neal CE; Meis LC
    Semin Nucl Med; 1994 Oct; 24(4):272-85. PubMed ID: 7817200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multicenter clinical trials of monoclonal antibody B72.3-GYK-DTPA 111In (111In-CYT-103; OncoScint CR103) in patients with colorectal carcinoma.
    Abdel-Nabi HH; Doerr RJ
    Targeted Diagn Ther; 1992; 6():73-88. PubMed ID: 1576351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of OncoScint scan to assess resectability of hepatic metastases from colorectal cancer.
    Su WT; Brachman M; O'Connell TX
    Am Surg; 2001 Dec; 67(12):1200-3. PubMed ID: 11768830
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Challenges in immunoscintigraphy of ovarian cancer.
    Kim EE; Kasi LP
    Gynecol Oncol; 1993 Mar; 48(3):283-4. PubMed ID: 8462895
    [No Abstract]   [Full Text] [Related]  

  • 19. OncoScint CR103 imaging in the surgical management of patients with colorectal cancer.
    Doerr RJ; Abdel-Nabi HH
    Targeted Diagn Ther; 1992; 6():89-109. PubMed ID: 1576352
    [No Abstract]   [Full Text] [Related]  

  • 20. Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging.
    Bohdiewicz PJ
    J Nucl Med Technol; 1998 Sep; 26(3):155-63; quiz 170-1. PubMed ID: 9755434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.